3 March 2021 - Eli Lilly’s Olumiant has received a UK NICE recommendation for the treatment of moderate-to-severe atopic dermatitis ...
2 March 2021 - The NHS prescription charge in England is set to increase to £9.35 from 1 April 2021 ...
26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for ...
25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...
25 February 2021 - NICE has today issued draft guidance for public consultation which recommends sapropterin (Kuvan, BioMarin) for treating phenylketonuria ...
24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...
24 February 2021 - NICE had intended to appraise omalizumab for the treatment of patients with chronic rhinosinusitis with nasal ...
22 February 2021 - The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2 positive breast ...
16 February 2021 - Lupin is disappointed that NICE has published an Appraisal Consultation Document recommending not to approve NaMuscla (mexiletine) ...
16 February 2021 - It’s back to the drawing board for bluebird bio and its discussions with NICE, which has ...
17 February 2021 - AstraZeneca and Daiichi Sankyo’s antibody drug conjugate Enhertu has scored a conditional marketing authorisation in the ...
15 February 2021 - The UK’s NICE has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of ...
12 February 2021 - bluebird bio’s beta thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s ...
12 February 2021 - An appeal period has now opened until 26 February 2021. ...
14 February 2021 - The aim of this paper is to examine generic competition in the UK, with a special focus ...